SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 110 filers reported holding SUTRO BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 1.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,211 | -36.0% | 4,960 | -14.3% | 0.00% | – |
Q2 2023 | $26,900 | +13.1% | 5,785 | +12.4% | 0.00% | – |
Q1 2023 | $23,775 | -42.8% | 5,146 | 0.0% | 0.00% | – |
Q4 2022 | $41,580 | +59.9% | 5,146 | +12.0% | 0.00% | – |
Q3 2022 | $26,000 | +36.8% | 4,595 | +23.8% | 0.00% | – |
Q2 2022 | $19,000 | -79.3% | 3,712 | -67.1% | 0.00% | – |
Q1 2022 | $92,000 | -44.9% | 11,270 | 0.0% | 0.00% | – |
Q4 2021 | $167,000 | -21.6% | 11,270 | 0.0% | 0.00% | – |
Q3 2021 | $213,000 | +131.5% | 11,270 | +129.0% | 0.00% | – |
Q2 2021 | $92,000 | +17.9% | 4,921 | +44.3% | 0.00% | – |
Q1 2021 | $78,000 | +14.7% | 3,410 | +8.6% | 0.00% | – |
Q4 2020 | $68,000 | +126.7% | 3,140 | +6.9% | 0.00% | – |
Q3 2020 | $30,000 | +42.9% | 2,937 | +10.7% | 0.00% | – |
Q2 2020 | $21,000 | +50.0% | 2,654 | +90.0% | 0.00% | – |
Q1 2020 | $14,000 | -33.3% | 1,397 | -26.4% | 0.00% | – |
Q4 2019 | $21,000 | +23.5% | 1,899 | +4.4% | 0.00% | – |
Q3 2019 | $17,000 | -19.0% | 1,819 | 0.0% | 0.00% | – |
Q2 2019 | $21,000 | +90.9% | 1,819 | +84.3% | 0.00% | – |
Q1 2019 | $11,000 | +22.2% | 987 | 0.0% | 0.00% | – |
Q4 2018 | $9,000 | – | 987 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 1,675,579 | $5,814,259 | 1.78% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,883,693 | $20,416,415 | 1.10% |
Kynam Capital Management, LP | 1,552,675 | $5,387,782 | 0.88% |
Parkman Healthcare Partners LLC | 1,182,168 | $4,102,123 | 0.75% |
Rubric Capital Management LP | 3,344,810 | $11,606,491 | 0.44% |
BVF INC/IL | 3,347,946 | $11,617,373 | 0.31% |
DAFNA Capital Management LLC | 283,079 | $982,284 | 0.31% |
SECTORAL ASSET MANAGEMENT INC | 432,339 | $1,500,216 | 0.29% |
Eversept Partners, LP | 769,638 | $2,670,644 | 0.23% |
Frazier Life Sciences Management, L.P. | 780,000 | $2,706,600 | 0.18% |